Approximately 32% of manufacturing sites supplying registered medicines to Australia are inspected directly by the TGA, while the remaining facilities rely on recognized overseas regulatory certifications. Therefore, understanding good manufacturing practices in Australia is essential for manufacturers seeking consistent regulatory compliance and inspection readiness. In this guide, you will learn how Good Manufacturing Practices (GMP) are applied under the TGA framework, explore the most important official PDF guidance, and follow a practical GMP inspection checklist to prepare confidently for your next TGA inspection.
Table of Contents
What Is Good Manufacturing Practices in Australia?
Good manufacturing practices in Australia define the quality standards that pharmaceutical manufacturers must follow to produce safe, effective, and consistently controlled medicines. The Therapeutic Goods Administration (TGA) enforces these requirements by adopting the PIC S Guide to GMP, which aligns Australia’s regulatory framework with internationally recognized GMP principles. Therefore, manufacturers must establish a robust pharmaceutical quality system, maintain validated processes, and demonstrate continuous compliance throughout the product lifecycle. Understanding these requirements not only supports regulatory approval but also strengthens GMP inspection readiness before every TGA inspection.
Why TGA GMP Inspections Focus on Quality Systems
TGA inspectors evaluate how effectively a manufacturer manages quality rather than simply reviewing documents. They assess whether the pharmaceutical quality system consistently controls manufacturing processes, prevents quality risks, and supports continuous improvement. Moreover, inspectors verify that validation, documentation, training, CAPA, and change control work together to maintain product quality. Therefore, organizations that build strong quality systems and prioritize GMP inspection readiness are better prepared to meet TGA expectations and reduce the risk of inspection findings.
Essential GMP Systems for TGA Inspection Readiness
Before a TGA inspection, manufacturers should strengthen several core GMP systems that directly influence compliance and inspection outcomes. The following official PIC/S guidance documents define the key requirements inspectors expect organizations to implement and maintain.
The following sections cover:
- PIC S Guide to GMP PE009-17 (PDF)
- Annex 11 Computerised Systems (PDF)
- Annex 15 Qualification and Validation (PDF)
- Annex 20 Quality Risk Management (PDF)
PIC/S Guide to GMP PE009-17 (PDF)
The PIC/S Guide to GMP PE009-17 defines the core GMP requirements adopted by the TGA for pharmaceutical manufacturing in Australia. It serves as the primary reference for quality systems, production, documentation, and inspection compliance.
Download PIC/S Guide to Good Manufacturing Practice for Medicinal Products PE 009-17 (Annexes)
Annex 11 Computerised Systems (PDF)
Annex 11 explains GMP requirements for computerized systems, including validation, electronic records, audit trails, and data integrity. It helps manufacturers maintain compliant digital quality systems.
Annex 15 Qualification and Validation (PDF)
Annex 15 describes how manufacturers should qualify facilities, equipment, utilities, and manufacturing processes before routine production. It also introduces a lifecycle approach to validation.
Annex 20 Quality Risk Management (PDF)
Annex 20 introduces Quality Risk Management principles for identifying, evaluating, and controlling quality risks throughout the product lifecycle. It supports science-based GMP decisions and continuous improvement.
Common TGA GMP Inspection Findings and How to Prevent Them
Even well-established pharmaceutical manufacturers receive GMP observations during TGA inspections. However, most findings result from weaknesses in quality systems rather than isolated technical errors. Therefore, organizations that strengthen their quality processes, investigate deviations effectively, and maintain inspection readiness can significantly reduce compliance risks before the next audit.
| Common Inspection Finding | Typical Cause | Recommended Preventive Action | Inspection Benefit |
|---|---|---|---|
|
Poor deviation investigations |
Weak root cause analysis |
Implement structured investigations and effective CAPA |
More effective corrective actions |
|
Computerised system deficiencies |
Missing validation, weak audit trails |
Validate computerized systems and strengthen data integrity controls |
Improved data reliability |
|
Validation gaps |
Incomplete process, cleaning, or equipment validation |
Maintain lifecycle validation and periodic reviews |
Greater process consistency |
|
Inadequate procedures |
Outdated or unclear SOPs |
Review and update procedures regularly |
Better GMP compliance |
|
Weak quality control |
Inconsistent testing or documentation |
Strengthen QC oversight and record review |
Improved product quality |
|
Poor training management |
Incomplete competency records |
Deliver ongoing GMP training and assess effectiveness |
Better inspection readiness |
The infographic below summarizes the most common TGA GMP inspection findings and the practical actions manufacturers can take to improve compliance and inspection readiness.
Australia GMP Inspection Readiness Checklist
Preparing for a TGA GMP inspection requires more than reviewing documents shortly before the audit. Instead, manufacturers should maintain a continuous state of inspection readiness by strengthening their quality systems, validating critical processes, and addressing potential compliance gaps early. The following checklist highlights the key areas that TGA inspectors commonly evaluate and helps organizations assess their readiness before an inspection.
The infographic below shows a practical TGA GMP inspection readiness roadmap, helping manufacturers move from PIC/S requirements to audit evidence and continuous compliance.
Final Words
More than 85% of TGA GMP inspections are completed within the agency’s target timeframe, demonstrating the importance of maintaining continuous compliance rather than preparing only before an audit. Therefore, organizations that implement good manufacturing practices in Australia as part of their daily operations can strengthen inspection readiness, reduce recurring compliance issues, and build a more resilient pharmaceutical quality system. As TGA continues to expand its risk-based inspection approach, continuous improvement remains the most effective strategy for long-term GMP compliance.
Quality Management System
We work with pharmaceutical teams to design, implement, and run effective Quality Management Systems, covering change control, CAPA, deviations, and audits to support consistent GMP compliance.
FAQ
TGA inspectors typically begin by reviewing the pharmaceutical quality system, quality documentation, and management oversight before assessing manufacturing operations and supporting records.
Manufacturers should maintain validated processes, current SOPs, effective CAPA, trained personnel, and complete documentation while performing regular internal GMP audits.
The most common observations involve data integrity, validation gaps, deviation management, change control, and incomplete quality documentation within regulated manufacturing operations.
References
Marco Klinger is Head of Quality Services at Zamann Pharma Support, where he leads consulting teams through complex regulatory and quality-driven projects. He brings more than 15 years of hands-on compliance experience across regulated industries. His work includes close collaboration with companies such as Reckitt, Sanofi, Biotech, Biotest, and others. Marco has deep expertise in medical device development, aseptic manufacturing, and the design, implementation, and management of complete quality management systems within GMP-regulated environments.